Sort by
Refine Your Search
-
Country
-
Program
-
Employer
- University of Oslo
- Umeå University
- Nature Careers
- University of Adelaide
- University of Helsinki
- Aarhus University
- Centre for Genomic Regulation
- European Molecular Biology Laboratory
- Harvard University
- SWINBURNE UNIVERSITY OF TECHNOLOGY
- Swinburne University of Technology
- Universitat Pompeu Fabra
- Universities of Aarhus (Denmark), Helsinki (Finland), Oslo (Norway) and Umeå (Sweden)
- 3 more »
- « less
-
Field
-
Medicine Norway at the University of Oslo is an international biomedical research centre, with the overall objective of translating basic medical research into clinical practice. The Nordic EMBL Partnership
-
Universities of Aarhus (Denmark), Helsinki (Finland), Oslo (Norway) and Umeå (Sweden) | Denmark, Maine | United States | 23 days ago
Medicine Norway at the University of Oslo is an international biomedical research centre, with the overall objective of translating basic medical research into clinical practice. The Nordic EMBL Partnership
-
for monogenic immune diseases. We use high-throughput biology techniques to optimize, develop and understand the CRISPR-Cas9 system that forms the base of the platform, and develop and implement methods
-
the NORPOD program. The work focuses on building a gene editing platform that can be used to correct patient-specific mutations in ex vivo cell therapies for monogenic immune diseases. We use high-throughput
-
Fellow position in the Haapaniemi
-
Galej at the EMBL Grenoble, France. We are looking for a highly motivated and ambitious individual to join our team interested in the structure and function of RNA-protein complexes. Our group
-
NORPOD is a collaborative postdoctoral program of the Nordic EMBL Partnership for Molecular Medicine . The partnership is a network of four national research centers across the Nordics and the
-
NORPOD is a collaborative postdoctoral program of the Nordic EMBL Partnership for Molecular Medicine . The partnership is a network of four national research centers across the Nordics and the
-
a gene editing platform that can be used to correct patient-specific mutations in ex vivo cell therapies for monogenic immune diseases. We use high-throughput biology techniques to optimize, develop
-
education to enable regions to expand quickly and sustainably. In fact, the future is made here. NORPOD is a collaborative postdoctoral program of the Nordic EMBL Partnership for Molecular Medicine